{
    "Trade/Device Name(s)": [
        "Nichols Advantage Aldosterone Assay"
    ],
    "Submitter Information": "Nichols Institute Diagnostics",
    "510(k) Number": "K050784",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CJM"
    ],
    "Summary Letter Date": "May 19, 2005",
    "Summary Letter Received Date": "May 26, 2005",
    "Submission Date": "May 13, 2005",
    "Regulation Number(s)": [
        "21CFR862.1045"
    ],
    "Regulation Name(s)": [
        "Aldosterone test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Aldosterone"
    ],
    "Specimen Type(s)": [
        "Serum",
        "EDTA plasma",
        "Extracted urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Nichols Advantage Specialty System"
    ],
    "Method(s)/Technology(ies)": [
        "Competitive immunochemiluminometric assay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Nichols Advantage Aldosterone Assay, a competitive immunochemiluminometric assay for quantitative measurement of aldosterone in serum, EDTA plasma, and extracted urine",
    "Indications for Use Summary": "Intended for in vitro diagnostic laboratory use with Nichols Advantage Specialty System for quantitative measurement of aldosterone in human serum, EDTA plasma, and extracted urine to aid in diagnosis and treatment of primary aldosteronism, hypertension, selective hypoaldosteronism, edematous states, and other electrolyte imbalance conditions",
    "fda_folder": "Clinical Chemistry"
}